Shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) [Trend Analysis] swings enthusiastically in regular trading session, it a gain of 4.44% to close at $27.05. Valeant Pharma announces ‘enhanced rebate program’ to reduce the price of Nitropress and Isuprel for all hospitals in the United States (VRX). The firm announced that, pursuant to a recommendation by its Patient Access and Pricing Committee, the company will make available to all hospitals in the United States an enhanced rebate program to reduce the price of Nitropress and Isuprel. Under the enhanced program, all hospitals are eligible for a rebate of at least 10%, with rebates totaling 20%, 30% or 40% based on volume purchased during a calendar quarter for hospitals that purchase large volumes of the relevant drug.
Hospitals will receive these discounts primarily through their group purchasing organization. Hospitals that don’t buy drugs through a GPO can access the program by contacting Valeant customer service. The rebate program is effective immediately, with hospitals receiving rebates after the end of the quarter in which the purchases were made. Moving forward to saw long-term intention, VRX experts calculate Return on Investment of 3.70%. The stock is going forward its fifty-two week low with 14.86% and lagging behind from its 52-week high price with -89.75%. VRX last month stock price volatility remained 8.76%.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) [Trend Analysis] knocking active thrust in leading trading session, shares an advance of 6.43% to 9.93 with around 1.58 Million shares have changed hands in this session. Inovio Pharma announces that testing of its synthetic vaccine for the Zika virus induced robust antibody and T cell responses in non-human primates (INO). The firm announced that testing of its synthetic vaccine for the Zika virus induced robust antibody and T cell responses in non-human primates (monkeys), demonstrating the product’s potential to prevent infection from this harmful pathogen.
Two doses of the Zika DNA vaccine delivered either intramuscularly or intradermally resulted in seroconversion, or the development of detectable specific antibodies in the blood, in all vaccinated non-human primates. Researchers also observed that vaccination generated robust and broad T cell responses as analyzed by the standardized T cell ELISPOT assay. “With positive large animal results in hand we are moving aggressively to initiate and conduct our first Zika vaccine human trial in 2016.” The stock is going forward its fifty-two week low with 120.67% and lagging behind from its 52-week high price with -15.06%. Likewise the positive performance for the quarter recorded as 51.14% and for the year was 24.59%, while the YTD performance remained at 47.77%. INO has Average True Range for 14 days of 0.62.
Biogen Inc. (NASDAQ:BIIB) [Trend Analysis] retains strong position in active trade, as shares scoring 1.61% to $266.26 in a active trade session, while looking at the shares volume, around 1.31 Million shares have changed hands in this session. Biogen (BIIB) announced collaboration w/ the UPenn to advance gene therapy and gene editing technologies. Under this broad research and development alliance, Penn will combine its extensive gene therapy resources and expertise to develop therapeutic candidates under the various collaboration programs using both existing and newly developed AAV vectors and will also aid in the development of new manufacturing approaches needed to support commercialization of gene therapy products. Biogen will in turn, leverage both its therapeutic area and target identification expertise and drug development capabilities to help advance the collaboration programs into the clinic and toward approval. The firm has institutional ownership of 88.30%, while insider ownership included 0.10%. BIIB attains analyst recommendation of 2.10 with week’s performance of -1.45%. Investors looking further ahead will note that the Price to next year’s EPS is 6.63%.